Clearmind Medicine 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Adi Zuloff-Shani

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	3.3yrs
CEO 소유권	n/a
경영진 평균 재임 기간	2.6yrs
이사회 평균 재임 기간	3.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Adi Zuloff-Shani 의 보수는 Clearmind Medicine 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jul 31 2024	n/a	n/a	-US$8m
Apr 30 2024	n/a	n/a	-US$7m
Jan 31 2024	n/a	n/a	-US$8m
Oct 31 2023	n/a	n/a	-US$9m
Jul 31 2023	n/a	n/a	-US$6m
Apr 30 2023	n/a	n/a	-US$7m
Jan 31 2023	n/a	n/a	-US$7m
Oct 31 2022	n/a	n/a	-US$7m
Jul 31 2022	n/a	n/a	-US$7m
Apr 30 2022	n/a	n/a	-US$7m
Jan 31 2022	n/a	n/a	-US$4m
Oct 31 2021	US$145k	US$113k	-US$3m

보상 대 시장: German 시장에서 비슷한 규모의 회사에 비해 Adi 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: Adi 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Adi Zuloff-Shani (55 yo)

3.3yrs

테뉴어

Dr. Adi Zuloff-Shani, Ph D., serves as Member of Scientific Advisory Board at N2OFF, Inc. (formerly known as Save Foods, Inc.) since October 2021. She serves as Chief Executive Officer of Clearmind Medicin...

리더십 팀

이름	위치	테뉴어	보상	소유권
Adi Zuloff-Shani	Chief Executive Officer	3.3yrs	데이터 없음	데이터 없음
Alan Rootenberg	Chief Financial Officer	2.4yrs	데이터 없음	0% € 0
Mark Haden	Vice President of Business Development	3.3yrs	데이터 없음	0% € 0
Mylene Touboul	Accounting Manager	no data	데이터 없음	데이터 없음
Gilad Babchuk	Head of Strategy & Communication	2.8yrs	데이터 없음	데이터 없음
Adi Varon	Controller	no data	데이터 없음	데이터 없음

2.6yrs

평균 재임 기간

69yo

평균 연령

경험이 풍부한 관리: CWY0 의 관리팀은 경험 ( 2.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mark Haden	Vice President of Business Development	3.3yrs	데이터 없음	0% € 0
John Krystal	Member of Scientific Advisory Board	2.4yrs	데이터 없음	데이터 없음
Michael Davidson	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Alon Friedman	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Wim van den Brink	Member of Scientific Advisory Board	3.1yrs	데이터 없음	데이터 없음
Oz Adler	Independent Director	2.9yrs	데이터 없음	0.0028% € 147.1
Amitai Weiss	Independent Chairman	5.3yrs	데이터 없음	0% € 0
Yehonatan Shachar	Independent Director	4.6yrs	데이터 없음	0% € 0
Gabriele Fischer	Member of Scientific Advisory Board	3.1yrs	데이터 없음	데이터 없음
Gal Yadid	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Christian Schutz	Member of Scientific Advisory Board	2.5yrs	데이터 없음	데이터 없음
Asaf Itzhaik	Director	1.9yrs	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: CWY0 의 이사회는 경험(평균 재직 기간 3.1 년)으로 간주됩니다.

Clearmind Medicine 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025

High number of new and inexperienced directors

Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023

Clearmind Medicine Inc. Appoints Dr. Fatima Cody Stanford, Associate Professor of Medicine At Massachusetts General Hospital and Harvard Medical School, to Its Scientific Advisory Board

Clearmind Medicine Inc. Announces Board Appointments

High number of new and inexperienced directors

Recent updates

Clearmind Medicine Inc., Annual General Meeting, Jan 06, 2025

Clearmind Medicine Inc. Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy

Clearmind Medicine Inc. Announces Publication of Its Patent Application for Innovative Ketamine-Based Combination Treatment

Clearmind Medicine Inc Grants U.S. Patent Approval for Binge Behavior Treatment

Clearmind Medicine Inc. Announces New Scientific Publication Shows MEAI's Potential as Novel Weight Loss Drug

Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss

Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders

Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression

Clearmind Medicine Receives Approval for Voluntary Delisting of its Common Shares from the Canadian Securities Exchange

Clearmind Medicine Obtains Clearance for Its Psychedelic- Based Alcoholism Clinical Trial

Clearmind Medicine Inc. Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration

Clearmind Medicine Inc. has completed a Follow-on Equity Offering in the amount of CAD 2.4 million.

Clearmind Medicine Inc. has completed a Follow-on Equity Offering.

Clearmind Medicine Inc. has filed a Follow-on Equity Offering.

Clearmind Medicine Inc. has filed a Follow-on Equity Offering.

Clearmind Medicine Announces Compliance with All Applicable Nasdaq Listing Standards

Scisparc Ltd. and Clearmind Medicine Inc. Announces Obesity Drug Showed Positive Results in A Pre-Clinical Trial

Scisparc Ltd. Obesity Drug Showed Positive Results in A Pre-Clinical Trial

High number of new and inexperienced directors

Clearmind Medicine Announces Positive Results from Its Weight Loss and Metabolic Disorder Program with Its Proprietary Psychedelic- Based Treatment

Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice

Clearmind Medicine Inc. to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities

Clearmind Medicine Inc. announced that it expects to receive $2.25 million in funding

Clearmind Medicine Inc., Annual General Meeting, Oct 19, 2023

SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Continues to Increase Its Patent Portfolio in the Field of Movement Abnormalities in the U.S

Clearmind Medicine Inc. Appoints Dr. Fatima Cody Stanford, Associate Professor of Medicine At Massachusetts General Hospital and Harvard Medical School, to Its Scientific Advisory Board

Clearmind Medicine Announces First US Site for Its Phase I/IIa Clinical Trial Evaluating Cmnd-100 in Patients with Alcohol Use Disorder

Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification

Clearmind Medicine Announces Irb Approval to Conduct Clinical Trial on Alcohol Use Disorder

Clearmind Medicine Inc. Announces Board Appointments

Clearmind Medicine Inc. Files Three Provisional Patent Applications with the United States Patent and Trademark Office

Clearmind Medicine Inc. Announces Positive Pre-Clinical Results Treating Major Depression with A Novel Ketamine-Based Compound

SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment

Clearmind Medicine Inc. Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

Clearmind Medicine Inc. Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder

Clearmind Medicine Inc. Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

Clearmind Medicine Inc. Completes IND-Enabling Studies for CMND-100

Clearmind Medicine Inc. Announces Initiation of CMND-100 Manufacturing Program to Address Its Upcoming Clinical Trial

High number of new and inexperienced directors

Clearmind Medicine Inc. Common Shares Deleted from OTC Equity

Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome

Clearmind Medicine Inc., Annual General Meeting, Dec 28, 2022

High number of new and inexperienced directors

CEO 보상 분석

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령